Back to top

Stoke Therapeutics Advances Zorevunersen in Dravet Syndrome Study

Stoke Therapeutics Advances Zorevunersen in Dravet Syndrome Study

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Stoke Therapeutics, Inc. (STOK)